TruScan RM - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TruScan RM


Thermo Scientific portable solutions deliver specialized identification and analysis of raw materials for the highly regulated global pharmaceutical industry.

With greater than 650 GMP facility installations worldwide, we’ve successfully implemented our solutions into the top pharmaceutical companies and regulatory enforcement agencies worldwide – enabling them to increase productivity and realize a rapid return on their investment.

We are more than the leading provider of portable analytical instruments. We are a true partner, delivering expertise and solutions to improve processes, reduce risk & costs, and achieve competitive advantage.

Developed with in-depth pharmaceutical industry experience, Thermo Scientific handheld analyzers provide manufacturers with a portable solution to achieve quality initiatives throughout the manufacturing process.
The Thermo Scientific TruScan RM, based on Raman spectroscopy, and the Thermo Scientific microPHAZIR RX, based on Near-Infrared spectroscopy, are simple to use and enable on-the-spot, actionable Pass-Fail results within seconds.
 
Both analyzers are 21 CFR part 11 compliant and meet the requirements of global pharmacopeias.  Our handheld solutions are used by 24 of the top 25 global pharmaceutical manufacturers, driving significant time and cost savings. 

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

 

Thermo Scientific – Portable Analytical Instruments

Website: www.thermoscientific.com/quality

E-mail: sales.chemid@thermofisher.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here